This video highlights the key insights from the 2025 Global Initiative for Chronic Obstructive Lung Disease (GOLD) report, presenting a clear, structured, and evidence-based approach to the diagnosis, assessment, and management of COPD.

This video highlights prurigo nodularis (PN) as a systemic disorder driven by neural inflammation and immune dysregulation. Key inflammatory mediators IL-4 and IL-13, along with fibrosis, emerge as central features, emphasizing the need for targeted therapies that address both neural and immune pathways. 

In bullous pemphigoid, autoimmunity to BP180 and BP230 is thought to trigger a type 2 inflammatory response. Read this article to find out more

Systemic corticosteroids and other immunosuppressants are the current mainstay of therapy but carry risks for patients with bullous pemphigoid. Read this article to find out more

The management of bullous pemphigoid is challenging and new treatment approaches are needed. Read this article to find out more.